Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
In total, 44.3% of patients received no prescriptions for osteoporosis medications during the pre-perioperative period, 35.4% were prescribed antiresorptive agents, and 8.1% were prescribed anabolic agents.Patient demographics (excluding comorbidities and concomitant medications)AllPVP groupSFS groupN = 4870N = 2675N = 2195Sex, n (%) Male1190 (24.4)623 (23.3)567 (25.8) Female3680 (75.6)2052 (76.7)1628 (74.2)Age, years Mean ± SD79.2 ± 6.980.2 ± 6.778.0 ± 6.8Age categories, n (%) 40 to 69 years425 (8.7)178 (6.7)247 (11.3) 70 to 79 years1949 (40.0)965 (36.1)984 (44.8) ≥ 80 years2496 (51.3)1532 (57.3)964 (43.9)Type of insurance, n (%) SHI31 (0.6)8 (0.3)23 (1.0) NHI1069 (22.0)528 (19.7)541 (24.6) LSEHS3770 (77.4)2139 (80.0)1631 (74.3)Drug classes for pre-perioperative osteoporosis medicationsa, n (%) No2155 (44.3)1348 (50.4)807 (36.8) Anabolic agents394 (8.1)128 (4.8)266 (12.1) Parathyroid hormone356 (7.3)121 (4.5)235 (10.7) Romosozumab38 (0.8)7 (0.3)31 (1.4) Antiresorptive agents1726 (35.4)863 (32.3)863 (39.3) Bisphosphonate1243 (25.5)639 (23.9)604 (27.5) Selective estrogen receptor modulator263 (5.4)143 (5.3)120 (5.5) Anti-RANKL220 (4.5)81 (3.0)139 (6.3) Combination of two or moreb15 (0.3)8 (0.3)7 (0.3) Bone metabolism-regulating drugs onlyc580 (11.9)328 (12.3)252 (11.5)Pre-preoperative osteoporosis medications status, n (%) Untreatedd2735 (56.2)1676 (62.7)1059 (48.2) Previously treated2135 (43.8)999 (37.3)1136 (51.8)History of fractures other than VF, n (%) No4105 (84.3)2296 (85.8)1809 (82.4) All hip fracture113 (2.3)62 (2.3)51 (2.3) NHNV fracture599 (12.3)289 (10.8)310 (14.1) Bothe53 (1.1)28 (1.0)25 (1.1)LSEHS latter-stage elderly health care system; NHI national health insurance; NHNV non-hip non-vertebral; PVP percutaneous vertebroplasty; RANKL receptor activator of nuclear factor kappa-B ligand; SD standard deviation; SFS spine fusion surgery; SHI society-managed employment-based health insurance association; VF vertebral fracturea “Anabolic agents” and “antiresorptive agents” also include patients who use those agents in combination with “bone metabolism-regulating drugs”b Excluding bone metabolism-regulating drugsc A general term that includes active vitamin D, vitamin K, and calciumd Untreated or bone metabolism-regulating drugs onlye Patients with a history of both all hip fractures together with NHNV during the baseline period
Source: Patient demographics. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Patients aged ≥ 40, diagnosed with VFs and osteoporosis, with initial spine surgery between April 2015 and February 2021, were analyzed using a Japanese claims database.
Source: Abstract.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Preoperative treatment and postoperative outcomes in osteoporotic patients with vertebral fractures: a longitudinal database study
Study design awaiting verification · Journal of Bone and Mineral Metabolism · 2025
Original publication title
Preoperative treatment and postoperative outcomes in osteoporotic patients with vertebral fractures: a longitudinal database study
© The Author(s) 2025
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
This study aimed to investigate perioperative treatment and postoperative outcomes in osteoporotic patients with vertebral fractures (VFs), categorized by the type of spine surgery.
Source: IntroductionAbstract: What methods does the paper describe?
Patients aged ≥ 40, diagnosed with VFs and osteoporosis, with initial spine surgery between April 2015 and February 2021, were analyzed using a Japanese claims database. Time-to-event analysis was conducted for postoperative outcome. Outcome-related factors were explored with a multivariable Cox proportional hazards model.
Source: Materials and methodsAbstract: Results
The study population (n = 4870) consisted of 2675 patients in the percutaneous vertebroplasty (PVP) group and 2195 in the spine fusion surgery (SFS) group. Most patients had lumbar VFs, and posterior spinal fusion was common in the SFS group. Approximately 20% of patients did not receive prescriptions for osteoporosis medications during the perioperative period. Most reoperations and subsequent fractures occurred within 90 days after PVP or SFS. In the PVP group, degenerative spine disease (adjusted hazard ratio 1.34 [95% CI, 1.03 to 1.76]), psychotropic drugs (1.34 [1.03 to 1.76]), and glucocorticoid prescriptions with a mean dose of ≥ 5 to < 7.5 mg/day (2.35 [1.04 to 5.34]) (vs. < 1 mg/day) were associated with reoperation.
In post hoc subgroup analysis by year of spine surgery, anabolic agents were associated with a lower risk of reoperation (0.48 [0.30 to 0.75]) in 2019 and later. In the SFS group, hyperparathyroidism and Parkinson’s disease were associated with reoperation (2.14 [1.03 to 4.44] and 2.10 [1.31 to 3.37], respectively).
Source: ResultsAbstract: Conclusion
Perioperative osteoporosis medication may be suboptimal. Factors associated with postoperative outcomes must be considered, with the strategic goal of improving patient outcomes.
Source: ConclusionAuthors’ abstract
Introduction
This study aimed to investigate perioperative treatment and postoperative outcomes in osteoporotic patients with vertebral fractures (VFs), categorized by the type of spine surgery.
Materials and methods
Patients aged ≥ 40, diagnosed with VFs and osteoporosis, with initial spine surgery between April 2015 and February 2021, were analyzed using a Japanese claims database. Time-to-event analysis was conducted for postoperative outcome. Outcome-related factors were explored with a multivariable Cox proportional hazards model.
Results
The study population (n = 4870) consisted of 2675 patients in the percutaneous vertebroplasty (PVP) group and 2195 in the spine fusion surgery (SFS) group. Most patients had lumbar VFs, and posterior spinal fusion was common in the SFS group. Approximately 20% of patients did not receive prescriptions for osteoporosis medications during the perioperative period. Most reoperations and subsequent fractures occurred within 90 days after PVP or SFS. In the PVP group, degenerative spine disease (adjusted hazard ratio 1.34 [95% CI, 1.03 to 1.76]), psychotropic drugs (1.34 [1.03 to 1.76]), and glucocorticoid prescriptions with a mean dose of ≥ 5 to < 7.5 mg/day (2.35 [1.04 to 5.34]) (vs. < 1 mg/day) were associated with reoperation.
In post hoc subgroup analysis by year of spine surgery, anabolic agents were associated with a lower risk of reoperation (0.48 [0.30 to 0.75]) in 2019 and later. In the SFS group, hyperparathyroidism and Parkinson’s disease were associated with reoperation (2.14 [1.03 to 4.44] and 2.10 [1.31 to 3.37], respectively).
Conclusion
Perioperative osteoporosis medication may be suboptimal. Factors associated with postoperative outcomes must be considered, with the strategic goal of improving patient outcomes.
Supplementary Information
The online version contains supplementary material available at 10.1007/s00774-025-01639-2.
Publication and source details
Original title: Preoperative treatment and postoperative outcomes in osteoporotic patients with vertebral fractures: a longitudinal database study
Ruriko Koto; Shiori Yoshida; Akihiro Nakajima; Tetsuya Miwa; Naohisa Miyakoshi
Journal of Bone and Mineral Metabolism · 2025
© The Author(s) 20252025https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Teijin Pharma LimitedRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T02:56:50.220358+00:00
DOI: 10.1007/s00774-025-01639-2 · PMC12701861